Wale, et al. - In view of the need for a multidisciplinary approach for a successful clinical nuclear therapy program using ²²³radium (Ra), researchers suggested an implementation strategy and made a brief discussion regarding potential new nuclear radiopharmaceuticals still under investigation offering the future possibility of radioligand therapy. Food and Drug Administration had approved ²²³Ra in 2013 for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases without visceral metastases. Due to its alpha-particle emissions, ²²³Ra offers an improved therapeutic profile resulting in a relatively higher linear energy transfer and lower particle range compared with beta-emitters. Patients receiving ²²³Ra demonstrate increased overall survival and delayed adverse skeletal events.